Memo Therapeutics AG’s Post

I am so proud to be part of a team that holds science innovation at the forefront of their business model! Ask me today how our humanized animal models can accelerate your preclinical research. #cancer #humanizedmice #oncology #AACR #immunology

🌟 Shaperon: Innovating Biotech Solutions 🌟 Shaperon is advancing treatments through its unique inflammatory complex inhibitors and nanobody technology. Key Pipelines: NuGel: Atopic dermatitis treatment in Phase 2 trials in the US, following success in Korea. NuCerin: Alzheimer’s treatment in Phase 1 trials in Korea. Papiliximab: Dual-target immuno-oncology drug nearing technology transfer post-preclinical success. With growing investments in R&D, Shaperon is positioned to lead in the global atopic dermatitis market. NuGel’s innovative mechanism and strong safety profile aim to surpass existing therapies. Despite financial challenges, Shaperon’s advancements in clinical trials and strategic partnerships offer promising growth potential. 🚀 Stay tuned for updates as we continue our journey of innovation! #Biotech #ClinicalTrials #Innovation #AtopicDermatitis #Shaperon #NuGel https://lnkd.in/eZDym5nW

 Exogenus Therapeutics secures strategic funding.  We're thrilled to announce a strategic investment led by 3xP Global, which will boost the development of #Exo-101, a promising biological medicine derived from umbilical cord blood, for regenerative medicine and inflammatory disorders. This investment will be used for scaling-up of production capabilities towards GMP standards, helping to bridge the gap from pre-clinical to clinical stages, positioning us one step closer to reach patients in need. It will also support team growth and expansion of Exogenus Therapeutics pipeline to reach other markets. Find out more about Exogenus Therapeutics at www.exogenus-t.com #ExogenusTherapeutics #3xPGlobal #Biotech #Innovation #HealthCareInvestement

Unlock the Future of Drug Screening with DefiniGEN's iPSC-Derived PFIC2 Cells!   Discover the game-changing advantages of our iPSC-derived PFIC2 cells in drug screening which overcome the common issues when screening with primary cells and mouse models:   Biological Relevance: Accurately mimic human disease phenotype. Consistency: No batch-to-batch variation since our cells are sourced from a single donor, giving you reproducible data. Scalability: We can scale to meet your extensive screening needs Our innovative technology addresses limitations of traditional models, paving the way for breakthroughs in PFIC2 therapeutics.   Learn more by reading our blog here: https://lnkd.in/eKspSV8F   #DrugDiscovery #iPSC #Pharma #Biotech #Innovation #DefiniGEN #PFIC

🆕 Announcing New Xchange! 🗞️📰 We are thrilled to announce the launch of our brand-new digital magazine, News Xchange! 🎉 🌍 Stay ahead of the curve with the very latest company updates and industry news from the world of life sciences, pharma, and biotech. Whether you're passionate about Antibody Therapeutics, Immunotherapies, Advanced Therapies, Oligonucleotide Therapeutics, or the revolutionary impact of AI in Drug Discovery, News Xchange has you covered. 🥽🧪🔬 💡 Explore thought leadership articles, emerging trends, and expert insights, all designed to keep you informed and inspired. 🔗 Check out News Xchange here: https://lnkd.in/dp443drW Let’s shape the future of healthcare together! 🌟 #HubXchange #NewsXchange #PharmaNews #BiotechNews #LifeSciences #Innovation #AdvancedTherapies #AIInDrugDiscovery #Biopharma #HealthcareInnovation #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

🔍 Need to accelerate your drug discovery program? Let us help you. BPS Bioscience Inc. offer screening services to quickly identify potential therapeutics, predict potency, and narrow down large pools of candidates to much smaller ones. Additionally, cell-based screening services are also available for a more comprehensive view of the biological context and resulting cellular responses. Follow the link for more information 👇 https://lnkd.in/ei9wwpMA #DrugDiscovery #Bioscience

TRENDING TOPIC: Accelerate innovation with ease with VHH power! Because of their ease of use for development of more advanced therapies such as bi- and multi-specifics and CAR-T, single-domain camelid antibodies are surging in popularity. Discover our state-of-the-art VHH antibody discovery platforms and dive into our showcased poster from Biologics UK. Let's connect to explore how we're advancing highly customizable VHH programs, offering a range of discovery methods to meet your specific needs. With decades of experience in VHH discovery, we're not just following trends - we're defining them. See the poster: https://bit.ly/4d7NRmq Connect to discuss your next innovation: https://bit.ly/3JsvCKW #VHH #TherapeuticBreakthrough #Bispecifics #Innovation #Antibodies #mAb #InSilico #Biotechnology #TechBio

Our CDO, Pascal Merchiers and Scientist, Laust Bavnhøj, are at the Antibody Engineering & Therapeutics Europe Conference in London this week.    If you are attending and would like to find out about Commit Biologics' BiCE™ Technology Platform and how it can supercharge a conventional monoclonal #antibody to activate the #ComplementSystem, please reach out.   To learn more, visit our website through the link in our comments below.   #AntibodyEngineeringandTherapeuticsEurope2024 #ImmuneResponse #ImmuneSystem #BiCEtechnology  

Extracellular #vesicles: setting-up the path to IND with advanced characterization packages #Extracellularvesicles (#EVs) are a promising delivery vehicle for various #biotherapeutics. #Advancedcharacterization is crucial for developing EV-based therapeutics, however, it is also challenging due to their diverse cargo and sizes. Next month, Lonza’s Davide Zocco (Director, Site Management) will discuss the intricacies of producing EV-based therapies, emphasizing the importance of precise analytics and process design to maintain control over product quality throughout #clinicaldevelopment Register for this upcoming #webinar below:

Optimized Molecules for Optimized Profiles: An AI-Driven Platform for Small Molecule Drug Discovery with Fred Manby from Iambic Therapeutics. Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need. Our platform enables us to widely explore chemical space, while also sampling a wide range of target product profiles. We have demonstrated our platform on initial programs, with our first scheduled for clinical entry just two years after launch. https://lnkd.in/eDBzUurr Save $150 with Discount code SPK150. #drugdiscoverychemistry